US FDA panel rejects BMS/AstraZeneca diabetes drug on cancer, liver injury concerns
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb's and AstraZeneca's chances of being the first to the US market with a sodium glucose co-transporter-2 (SGLT-2) inhibitor may be in jeopardy after a US FDA advisory panel was unwilling to back the firms' investigational Type II diabetes drug dapagliflozin.